IMROZ subgroup analysis 

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Presented by Dr. Thomas Martin, this IMROZ subgroup analysis demonstrated that adding isatuximab to standard VRd therapy improved progression-free survival and deepened responses in transplant-ineligible patients with newly diagnosed multiple myeloma and 1q21+ status, a high-risk cytogenetic subgroup.

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study